Duke Cancer Institute

Name

Duke Cancer Institute

Legal name

Duke Cancer Institute

Website

https://dukecancerinstitute.org

Company type

Private

Founded year

1972

Operating status

Operating

Headcount range

501–1,000 employees

Ownership category

akta.pro rank

Product category

Academic Cancer Treatment and Research

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511)

SIC

Services-Health Services (8000), Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM)

akta.pro secondary industries

Biomedical Sciences & Medical Research Institutes (University-Based) (EDAHAGAI), Oncology & Cancer Specialty Hospitals (HLAFAHAC), Oncology Specialty Pharmaceuticals (HLAIACAA)

Keywords

• Cancer treatment services
• Clinical oncology trials
• Precision cancer medicine
• Cancer research programs
• Oncology patient care

Headquarters

HQ city

Durham

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure

Revenue model

1. Healthcare Services and Clinical Care: Revenue generated through patient care services including cancer treatment, clinical trials, and diagnostic services provided through Duke Health system
2. Research Funding and Grants: NCI Cancer Center Support Grant (P30 CCSG) and peer-reviewed cancer research funding from federal agencies including NIH and NCI
3. Philanthropy and Giving: Donations and gifts to support cancer research, patient care, and facility improvements through Duke University's development office

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Core offering

Duke Cancer Institute provides comprehensive cancer care to patients — from diagnosis through survivorship — delivered through multidisciplinary Centers of Excellence, the Oncology Access Center, and clinical trials. The institute also runs cancer research programs supported by 14 shared scientific resources covering genomics, proteomics, imaging, animal models, and bioinformatics, and operates community outreach, patient navigation, and trainee education programs across a multi-state catchment area.

Product overview

Duke Cancer Institute is a premier cancer center offering a comprehensive portfolio of clinical services, research programs, and educational initiatives. The Institute provides direct patient care through its Oncology Access Center and clinical trials program, supported by 14 specialized shared resources including genomics, proteomics, imaging, and animal model facilities. Research activities are organized into 7 research programs spanning cancer biology, immuno-oncology, precision medicine, and prevention. The Institute operates 8 Centers of Excellence for specialized cancer types including brain tumors, immunotherapy, prostate cancer, and sarcoma. Community engagement is supported through outreach programs serving a catchment area of 67 North Carolina counties, 32 Virginia counties, and 6 South Carolina counties, with patient navigation and health ambassador training services. DCI also supports nearly 1,300 trainees from middle school through junior faculty.

Differentiator

Problem solved

Functional benefit

Brands

• Preston Robert Tisch Brain Tumor Center: Center specializing in primary brain cancer research and treatment
• Duke Center for Brain and Spine Metastasis
• Molecular Tumor Board
• Center for Cancer Immunotherapy
• Duke Sarcoma Center
• Center for Prostate and Urologic Cancers
• Supportive Care and Survivorship Center

Products and services

• Clinical Trials
• Oncology Access Center
• Patient Navigation Services
• Community Outreach and Engagement
• Preston Robert Tisch Brain Tumor Center
• Duke Center for Brain and Spine Metastasis
• Center for Cancer Immunotherapy
• Center for Prostate and Urologic Cancers
• Duke Sarcoma Center
• Supportive Care and Survivorship Center
• Center for Onco-Primary Care
• Molecular Tumor Board
• Cancer Research Training and Education Coordination
• Annual Health Screening and Awareness Event
• Community Health Ambassador Program
• Cancer InFocus

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Citrus OncologycoreStrategic or Co-development Partner · 27 February 2026Duke Cancer Institute partnered with Citrus Oncology. The partnership focuses on privacy options and data handling related to targeted advertising and sales opt-outs in the oncology context.
• Duke Primary Care-CroasdailecoreStrategic or Co-development PartnerAnnual Health Screening and Awareness Event partnership providing free cancer screenings to community members
• Lincoln Community Health CentercoreStrategic or Co-development PartnerPartnership for annual health screening events providing free prostate, skin, and colon cancer screenings
• Community Advisory CouncilcoreGTM or Marketing PartnerAdvisory council including survivors, caregivers, and community advocates representing diverse populations across catchment area to guide community outreach efforts
• Duke Health SystemcoreStrategic or Co-development PartnerIntegrated healthcare delivery system providing patient referrals, shared facilities, and coordinated care across Duke University medical centers
• Leica MicrosystemsminorStrategic or Co-development PartnerDuke and Leica Microsystems established a Center of Excellence for microscopy to advance cancer research imaging capabilities

Scale indicators6 records

Recent moves10 records

Expansion highlights5 records

Direct peers

• UNC Lineberger Comprehensive Cancer Center: UNC-affiliated NCI-designated Comprehensive Cancer Center located in neighboring North Carolina. Direct regional peer competing for the same catchment population, faculty, and NCI funding.
• Dana-Farber Cancer Institute: Harvard-affiliated NCI-designated Comprehensive Cancer Center with leading clinical trials and precision oncology programs. Highly comparable research and patient-care model integrated with a major academic medical center.
• Memorial Sloan Kettering Cancer Center: NCI-designated Comprehensive Cancer Center with deep translational research portfolio and clinical trials program. Directly comparable as a peer academic oncology institution with disease-specific centers of excellence.
• Fred Hutchinson Cancer Center: NCI-designated Comprehensive Cancer Center in Seattle with leading immunology, immunotherapy, and translational research programs. Comparable research intensity and clinical trial pipeline.
• Winship Cancer Institute of Emory University: Emory-affiliated NCI-designated Comprehensive Cancer Center in the Southeast. Comparable scope of disease-specific centers, shared resources, and clinical trial portfolio.
• Abramson Cancer Center (Penn Medicine): University of Pennsylvania's NCI-designated Comprehensive Cancer Center with strong translational research and precision medicine programs. Comparable academic cancer center model with shared resource infrastructure.
• Vanderbilt-Ingram Cancer Center: NCI-designated Comprehensive Cancer Center at Vanderbilt University with shared resources and clinical trial programs. Comparable mid-sized academic cancer center structure and Southeast US positioning.
• Mayo Clinic Cancer Center: NCI-designated multi-site Comprehensive Cancer Center with extensive clinical trials and disease-specific programs. Comparable to DCI in multidisciplinary care, shared resources, and training pipeline.
• UCSF Helen Diller Family Comprehensive Cancer Center: UCSF's NCI-designated Comprehensive Cancer Center with strong precision oncology, immunotherapy, and population-science programs. Comparable academic cancer center with comparable scale of research and training.
• The University of Texas MD Anderson Cancer Center: NCI-designated Comprehensive Cancer Center and globally leading oncology hospital. Most comparable to DCI across clinical care, research, training, and shared-resource infrastructure serving a multi-state catchment.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/dukecancer
• YouTubeyoutube.com/user/dukecancerinstitute
• Facebookfacebook.com/dukecancerinstitute
• Instagraminstagram.com/dukecancerinstitute
• LinkedInlinkedin.com/company/duke-cancer-institute

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Duke Cancer Institute